Literature DB >> 34298128

A comprehensive study of a 29-capsid AAV library in a non-human primate central nervous system.

Oleksandr Kondratov1, Liudmyla Kondratova2, Ronald J Mandel3, Kirsten Coleman4, Michael A Savage5, Heather L Gray-Edwards6, Timothy J Ness7, Edgar Rodriguez-Lebron8, Robert D Bell9, Joseph Rabinowitz9, Paul D Gamlin5, Sergei Zolotukhin10.   

Abstract

Non-human primates (NHPs) are a preferred animal model for optimizing adeno-associated virus (AAV)-mediated CNS gene delivery protocols before clinical trials. In spite of its inherent appeal, it is challenging to compare different serotypes, delivery routes, and disease indications in a well-powered, comprehensive, multigroup NHP experiment. Here, a multiplex barcode recombinant AAV (rAAV) vector-tracing strategy has been applied to a systemic analysis of 29 distinct, wild-type (WT), AAV natural isolates and engineered capsids in the CNS of eight macaques. The report describes distribution of each capsid in 15 areas of the macaques' CNS after intraparenchymal (putamen) injection, or cerebrospinal fluid (CSF)-mediated administration routes (intracisternal, intrathecal, or intracerebroventricular). To trace the vector biodistribution (viral DNA) and targeted tissues transduction (viral mRNA) of each capsid in each of the analyzed CNS areas, quantitative next-generation sequencing analysis, assisted by the digital-droplet PCR technology, was used. The report describes the most efficient AAV capsid variants targeting specific CNS areas after each route of administration using the direct side-by-side comparison of WT AAV isolates and a new generation of rationally designed capsids. The newly developed bioinformatics and visualization algorithms, applicable to the comparative analysis of several mammalian brain models, have been developed and made available in the public domain.
Copyright © 2021 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AAV; CNS; ICM; ICV; IT; NGS; NHP; ddPCR; putamen

Mesh:

Substances:

Year:  2021        PMID: 34298128      PMCID: PMC8417503          DOI: 10.1016/j.ymthe.2021.07.010

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   12.910


  30 in total

1.  Altering Tropism of rAAV by Directed Evolution.

Authors:  Damien Marsic; Sergei Zolotukhin
Journal:  Methods Mol Biol       Date:  2016

2.  Neurotropic Properties of AAV-PHP.B Are Shared among Diverse Inbred Strains of Mice.

Authors:  Yasunori Matsuzaki; Masami Tanaka; Sachiko Hakoda; Tatsuki Masuda; Ryota Miyata; Ayumu Konno; Hirokazu Hirai
Journal:  Mol Ther       Date:  2019-02-28       Impact factor: 11.454

Review 3.  Gene therapy clinical trials worldwide to 2012 - an update.

Authors:  Samantha L Ginn; Ian E Alexander; Michael L Edelstein; Mohammad R Abedi; Jo Wixon
Journal:  J Gene Med       Date:  2013-02       Impact factor: 4.565

4.  Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain.

Authors:  Yasunori Matsuzaki; Ayumu Konno; Ryuta Mochizuki; Yoichiro Shinohara; Keisuke Nitta; Yukihiro Okada; Hirokazu Hirai
Journal:  Neurosci Lett       Date:  2017-11-24       Impact factor: 3.046

5.  Large-scale cellular-resolution gene profiling in human neocortex reveals species-specific molecular signatures.

Authors:  Hongkui Zeng; Elaine H Shen; John G Hohmann; Seung Wook Oh; Amy Bernard; Joshua J Royall; Katie J Glattfelder; Susan M Sunkin; John A Morris; Angela L Guillozet-Bongaarts; Kimberly A Smith; Amanda J Ebbert; Beryl Swanson; Leonard Kuan; Damon T Page; Caroline C Overly; Ed S Lein; Michael J Hawrylycz; Patrick R Hof; Thomas M Hyde; Joel E Kleinman; Allan R Jones
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

Review 6.  Viral Strategies for Targeting the Central and Peripheral Nervous Systems.

Authors:  Claire N Bedbrook; Benjamin E Deverman; Viviana Gradinaru
Journal:  Annu Rev Neurosci       Date:  2018-04-25       Impact factor: 12.449

7.  Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates.

Authors:  Kathrin Meyer; Laura Ferraiuolo; Leah Schmelzer; Lyndsey Braun; Vicki McGovern; Shibi Likhite; Olivia Michels; Alessandra Govoni; Julie Fitzgerald; Pablo Morales; Kevin D Foust; Jerry R Mendell; Arthur H M Burghes; Brian K Kaspar
Journal:  Mol Ther       Date:  2014-10-31       Impact factor: 11.454

8.  Direct Head-to-Head Evaluation of Recombinant Adeno-associated Viral Vectors Manufactured in Human versus Insect Cells.

Authors:  Oleksandr Kondratov; Damien Marsic; Sean M Crosson; Hector R Mendez-Gomez; Oleksandr Moskalenko; Mario Mietzsch; Regine Heilbronn; Jonathan R Allison; Kari B Green; Mavis Agbandje-McKenna; Sergei Zolotukhin
Journal:  Mol Ther       Date:  2017-08-10       Impact factor: 11.454

Review 9.  Brains, genes, and primates.

Authors:  Juan Carlos Izpisua Belmonte; Edward M Callaway; Sarah J Caddick; Patricia Churchland; Guoping Feng; Gregg E Homanics; Kuo-Fen Lee; David A Leopold; Cory T Miller; Jude F Mitchell; Shoukhrat Mitalipov; Alysson R Moutri; J Anthony Movshon; Hideyuki Okano; John H Reynolds; Dario Ringach; Terrence J Sejnowski; Afonso C Silva; Peter L Strick; Jun Wu; Feng Zhang
Journal:  Neuron       Date:  2015-05-06       Impact factor: 17.173

10.  Helper-free Production of Laboratory Grade AAV and Purification by Iodixanol Density Gradient Centrifugation.

Authors:  Sean M Crosson; Peter Dib; J Kennon Smith; Sergei Zolotukhin
Journal:  Mol Ther Methods Clin Dev       Date:  2018-05-08       Impact factor: 6.698

View more
  6 in total

Review 1.  Viral Tools for Neural Circuit Tracing.

Authors:  Qing Liu; Yang Wu; Huadong Wang; Fan Jia; Fuqiang Xu
Journal:  Neurosci Bull       Date:  2022-09-22       Impact factor: 5.271

Review 2.  Gene-based therapeutics for rare genetic neurodevelopmental psychiatric disorders.

Authors:  Beverly L Davidson; Guangping Gao; Elizabeth Berry-Kravis; Allison M Bradbury; Carsten Bönnemann; Joseph D Buxbaum; Gavin R Corcoran; Steven J Gray; Heather Gray-Edwards; Robin J Kleiman; Adam J Shaywitz; Dan Wang; Huda Y Zoghbi; Terence R Flotte; Sitra Tauscher-Wisniewski; Cynthia J Tifft; Mustafa Sahin
Journal:  Mol Ther       Date:  2022-05-17       Impact factor: 12.910

Review 3.  Molecular Therapies for Myotonic Dystrophy Type 1: From Small Drugs to Gene Editing.

Authors:  Mariapaola Izzo; Jonathan Battistini; Claudia Provenzano; Fabio Martelli; Beatrice Cardinali; Germana Falcone
Journal:  Int J Mol Sci       Date:  2022-04-21       Impact factor: 6.208

Review 4.  Adeno-Associated Viruses for Modeling Neurological Diseases in Animals: Achievements and Prospects.

Authors:  Evgenii Lunev; Anna Karan; Tatiana Egorova; Maryana Bardina
Journal:  Biomedicines       Date:  2022-05-15

5.  Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders.

Authors:  Jihad El Andari; Edith Renaud-Gabardos; Warut Tulalamba; Jonas Weinmann; Louise Mangin; Quang Hong Pham; Susanne Hille; Antonette Bennett; Esther Attebi; Emanuele Bourges; Christian Leborgne; Nicolas Guerchet; Julia Fakhiri; Chiara Krämer; Ellen Wiedtke; Robert McKenna; Laurence Guianvarc'h; Magali Toueille; Giuseppe Ronzitti; Matthias Hebben; Federico Mingozzi; Thierry VandenDriessche; Mavis Agbandje-McKenna; Oliver J Müller; Marinee K Chuah; Ana Buj-Bello; Dirk Grimm
Journal:  Sci Adv       Date:  2022-09-21       Impact factor: 14.957

Review 6.  Red Light Optogenetics in Neuroscience.

Authors:  Kimmo Lehtinen; Miriam S Nokia; Heikki Takala
Journal:  Front Cell Neurosci       Date:  2022-01-03       Impact factor: 5.505

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.